Ryvu Therapeutics SA
WSE:RVU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
PL |
|
Kennedy-Wilson Holdings Inc
NYSE:KW
|
US |
|
WASGAU Produktions & Handels AG
F:MSH
|
DE |
|
US Global Investors Inc
NASDAQ:GROW
|
US |
|
A O Smith Corp
NYSE:AOS
|
US |
|
E
|
Earthstone Energy Inc
F:BSC2
|
US |
|
Digital Brands Group Inc
NASDAQ:DBGI
|
US |
|
P
|
Providence Resources PLC
LSE:PVR
|
IE |
|
F
|
Flight Centre Travel Group Ltd
F:FLI
|
AU |
|
N
|
NNIT A/S
F:5NN
|
DK |
|
Westell Technologies Inc
OTC:WSTL
|
US |
|
Moonpig Group PLC
LSE:MOON
|
UK |
|
Nemaura Medical Inc
OTC:NMRD
|
US |
|
Cardinal Energy Ltd (Alberta)
TSX:CJ
|
CA |
|
Core Laboratories NV
NYSE:CLB
|
NL |
|
AJ Lucas Group Ltd
ASX:AJL
|
AU |
|
Curtis Banks Group PLC
LSE:CBP
|
UK |
Wall Street
Price Targets
RVU Price Targets Summary
Ryvu Therapeutics SA
According to Wall Street analysts, the average 1-year price target for RVU is 47.76 PLN with a low forecast of 27.27 PLN and a high forecast of 104.27 PLN.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RVU's stock price target?
Price Target
47.76
PLN
According to Wall Street analysts, the average 1-year price target for RVU is 47.76 PLN with a low forecast of 27.27 PLN and a high forecast of 104.27 PLN.
What is Ryvu Therapeutics SA's Revenue forecast?
Projected CAGR
12%
For the last 11 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 18%. The projected CAGR for the next 3 years is 12%.
